OXiGENE is a clinical-stage, biopharmaceutical company primarily focused on the development of vascular disrupting agents for the treatment of cancer. Co. has two clinical stage product candidates that are being developed in three oncology indications. Co.'s primary compound, fosbretabulin tromethamine, is being tested in two indications, recurrent ovarian cancer and gastrointestinal neuroendocrine tumors, and its second compound, OXi4503, is being tested in patients with relapsed or refractory acute myelogenous leukemia or myelodysplastic syndromes.